2-amino-7-(1-methylethyl)5-oxo-5H-[1]benzopyrano[2,3- b]pyridine-3-carboxylic acid; AA 673; CHX 3673; Elics
68302-57-8
298.3
C16H14N2O4
DMF, DMSO
-20°C
Amlexanox improves obesity-related metabolic dysfunction in mouse models. It increases thermogenesis and weight loss, decreases steatosis and improves insulin sensitivity. Clinically useful in treatment of aphthus ulsers.
Amlexanox acts by Inhibiting TANK-binding kinase 1(TBK1) and IKKԑ (IC50=1.2 µM). It induces the complete and reversible non-apoptotic inhibition of cell migration and proliferation, and although amlexanox does not induce either the down-regulation of F-actin levels or the depolymerization of actin filaments, it does induce the tyrosine phosphorylation of cortactin, a Src substrate known to regulate actin bundling.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
